Ticker

Analyst Price Targets — AEMD

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
August 18, 2026 10:46 amSwayampakula RamakanthH.C. Wainwright$1.50$2.94StreetInsider H.C. Wainwright Reiterates Neutral Rating on Aethlon Medical (AEMD)

Latest News for AEMD

Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 and 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term…

Globe News Wire • Aug 19, 2026
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®

Second cohort findings consistent with previously reported observations; independent statistical analysis planned following completion of all three patient cohorts SAN DIEGO, July 13, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company developing products to treat cancer and life-threatening viral infections, today announced that patients in the second cohort of its Australian…

PRNewsWire • Jul 13, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for AEMD.

No House trades found for AEMD.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top